The future role of gut hormones in the treatment of obesity

Therapeutic Advances in Chronic Disease

Volumn 5, Issue 1, 2014, Pages 4-14

  Troke, Rachel C ^a   Tan, Tricia M ^a   Bloom, Steve R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

GLP 1; Obesity; Oxyntomodulin; Peptide YY; Therapeutic

Indexed keywords

EXENDIN 4; GASTROINTESTINAL HORMONE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY;

AMINO ACID SEQUENCE; FOOD INTAKE; GLYCEMIC CONTROL; HUMAN; HYPERPLASIA; HYPOTHALAMUS; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; NONHUMAN; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STOMACH EMPTYING; WEIGHT REDUCTION;

EID: 84898910135     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313506730     Document Type: Review

References (87)

1. Acosta A. Hurtado M. Gorbatyuk O. La Sala M. Duncan D. Aslanidi G. et al. (2011) Salivary PYY: a putative bypass to satiety. PloS ONE 6 (10): e26137.
2. Adrian T. Bloom S. Bryant M. Polak J. Heitz P. Barnes A. (1976) Distribution and release of human pancreatic polypeptide. Gut 17: 940–944.
3. Adrian T. Greenberg G. Besterman H. Bloom S. (1978) Pharmacokinetics of pancreatic polypeptide in man. Gut 19: 907–909.
4. Asakawa A. Inui A. Kaga T. Katsuura G. Fujimiya M. Fujino M. et al. (2003 a) Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52: 947–952.
5. Asakawa A. Inui A. Yuzuriha H. Ueno N. Katsuura G. Fujimiya M. et al. (2003 b) Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124 (5): 1325–1336.
6. Asakawa A. Uemoto M. Ueno N. Katagi M. Fujimiya M. Fujino K. et al. (2006) Peptide YY3-36 and pancreatic polypeptide suppress food intake. J Gastroenterol Hepatol 21: 1501–1502.
7. Banerjee A. Onyuksel H. (2012) Human pancreatic polypeptide in a phospholipid-based micellar formulation. Pharm Res 29: 1698–1711.
8. Batterham R. Le Roux C. Cohen M. Park A. Ellis S. Patterson M. et al. (2003 a) Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88: 3989–3992.
9. Batterham R. Cohen M. Ellis S. Le Roux C. Withers D. Frost G. et al. (2003 b) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349: 941–948.
10. Batterham R. Cowley M. Small C. Herzog H. Cohen M. Dakin C. et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650–654.
11. Batterham R. Heffron H. Kapoor S. Chivers J. Chandarana K. Herzog H. et al. (2006) Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4: 223–233.
12. Beckman L. Beckman T. Sibley S. Thomas W. Ikramuddin S. Kellogg T. et al. (2011) Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. J Parenteral Enteral Nutrition 35: 169–180.
13. Bellmann-Sickert K. Elling C. Madsen A. Little P. Lundgren K. Gerlach L. et al. (2011) Long-acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation. J Med Chem 54: 2658–2667.
14. Berntson G. Zipf W. O'Dorisio T. Hoffman J. Chance R. (1993) Pancreatic polypeptide infusions reduce food intake in Prader–Willi syndrome. Peptides 14: 497–503.
15. Borg C. Le Roux C. Ghatei M. Bloom S. Patel A. Aylwin S. (2006) Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg 93: 210–215.
16. Buse J. Rosenstock J. Sesti G. Schmidt W. Montanya E. Brett J. et al. (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39–47.
17. Butler P. Elashoff M. Elashoff R. Gale E. (2013) A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 36: 2118–2125.
18. Christensen R. Kristensen P. Bartels E. Bliddal H. Astrup A. (2007) Efficacy and Safety of the weight loss drug Rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706–1713.
19. Cohen M. Ellis S. Le Roux C. Batterham R. Park A. Patterson M. et al. (2003) Oxyntomodulin suppresses appetite and decreases food intake in humans. J Clin Endocrinol Metab 88: 4696–4701.
20. Creutzfeldt W. Kleine N. Willms B. Orskov C. Holst J. Nauck M. (1996) Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide-1(7-36)amide in type 1 diabetic patients. Diabetes Care 19: 580–586.
21. Cummings D. Weigle D. Frayo R. Breen P. Ma M. Dellinger E. et al. (2002) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 346: 1623–1630.
22. Dakin C. Gunn I. Small C. Edwards C. Hay D. Smith D. et al. (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology 142: 4244–4250.
23. Dakin C. Small C. Batterham R. Neary N. Cohen M. Patterson M. et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145: 2687–2695.
24. Dakin C. Small C. Park A. Seth A. Ghatei M. Bloom S. (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight than in pair fed rats Am J Physiol Endocrinol Metab 283 (6): E1173–E1177.
25. Davis J. Perello M. Choi D. Magrisso I. Kirchner H. Pfluger P. et al. (2012) GOAT induced ghrelin acylation regulates hedonic feeding. Horm Behav 62: 598–604.
26. Day J. Ottaway N. Patterson J. Gelfanov V. Smiley D. Gidda J. et al. (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5: 749–757.
27. Druce M. Neary N. Small C. Milton J. Monteiro M. Patterson M. et al. (2006) Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers. Int J Obes (Lond) 30: 293–296.
28. Druce M. Wren A. Park A. Milton J. Patterson M. Frost G. et al. (2005) Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 29: 1130–1136.
29. Drucker D. Buse J. Taylor K. Kendall D. Trautmann M. Zhuang D. et al. (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372: 1240–1250.
30. Essah P. Levy J. Sistrun S. Kelly S. Nestler J. (2007) Effect of macronutrient composition on postprandial peptide YY levels. J Clin Endocrinol Metab 92: 4052–4055.
31. Fazen C. Valentin D. Fairchild T. Doyle R. (2011) Oral delivery of the appetite suppressing peptide hPYY(3−36) through the vitamin B 12 uptake pathway. J Medicinal Chem 54: 8707–8711.
32. Field B. Wren A. Peters V. Baynes K. Martin N. Patterson M. et al. (2010) PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 59: 1635–1639.
33. Foresight (2007) Tackling obesities: future choices–Modelling Future Trends in Obesity & Their Impact on Health, 2nd Edition. Project report, Government Office for Science. Available at: http://www.foresight.gov.uk/Obesity/obesity_final/Index.htm.
34. Fosgerau K. Skovgaard M. Larsen S. Meier E. Bæk C. Grøndahl C. et al. (2011) The new glucagon-GLP-1 dual agonist ZP 2929 in combination with long-acting insulin improves glycemic control without causing weight gain in db / db mice. Poster at American Diabetes Association (ADA)’s 71st Scientific Sessions, San Diego, CA, 24–28 June 2011.
35. Gantz I. Erondu N. Mallick M. Musser B. Krishna R. Tanaka W. et al. (2007) Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 92: 1754–1757.
36. Gibbons C. Caudwell P. Finlayson G. Webb D. Hellström P. Näslund E. et al. (2013) Comparison of postprandial profiles of ghrelin, active GLP-1, and total PYY to meals varying in fat and carbohydrate and their association with hunger and the phases of satiety. J Clin Endocrinol Metab 98 (5): E847–E855.
37. Gualillo O. Lago F. Dieguez C. (2008) Introducing GOAT: a target for obesity and anti-diabetic drugs? Trends Pharmacol Sci 29: 398–401.
38. Health and Social Care Information Centre (2013) Statistics on Obesity, Physical Activity and Diet: England, 2013. Available at: http://www.hscic.gov.uk/catalogue/PUB10364/obes-phys-acti-diet-eng-2013-rep.pdf
39. Herrmann C. Goke R. Richter G. Fehmann H. Arnold R. Goke B. (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117–126.
40. James W. Caterson I. Coutinho W. Finer N. van Gaal L. Maggioni A. et al. (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363: 905–917.
41. Jesudason D. Monteiro M. McGowan B. Neary N. Park A. Philippou E. et al. (2007) Low-dose pancreatic polypeptide inhibits food intake in man. Br J Nutr 97: 426–429.
42. Laferrère B. Swerdlow N. Bawa B. Arias S. Bose M. Oliván B. et al. (2010) Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab 95: 4072–4076.
43. Larsson L. Sundler F. Håkanson R. (1975) Immunohistochemical localization of human pancreatic polypeptide (HPP) to a population of islet cells. Cell Tissue Res 156: 167–171.
44. Le Roux C. Aylwin S. Batterham R. Borg C. Coyle F. Prasad V. et al. (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243: 108–114.
45. Le Roux C. Welbourn R. Werling M. Osborne A. Kokkinos A. Laurenius A. et al. (2007) Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246: 780–785.
46. Lin S. Shi Y. Yulyaningsih E. Aljanova A. Zhang L. Macia L. et al. (2009) Critical role of arcuate Y 4 receptors and the melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. PloS ONE 4 (12): e8488.
47. Lluis F. Fujimura M. Gómez G. Salvá J. Greeley G. JC. T. (1989) Cellular localization, half-life, and secretion of peptide YY. Rev Esp Fisiol 45: 377–384.
48. Marco J. Zulueta M. Correas I. Villanueva M. (1980) Reduced pancreatic polypeptide secretion in obese subjects. J Clin Endocrinol Metab 50: 744–747.
49. Merchenthaler I. Lane M. Shughrue P. (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403: 261–280.
50. Mondal M. Date Y. Yamaguchi H. Toshinai K. Tsuruta T. Kangawa K. et al. (2005) Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus. Regul Pept 126: 55–59.
51. Nauck M. (2013) A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care 36: 2126–2132.
52. Neary N. McGowan B. Monteiro M. Jesudason D. Ghatei M. Bloom S. (2008) No evidence of an additive inhibitory feeding effect following PP and PYY 3-36 administration. Int J Obes (Lond) 32: 1438–1440.
53. Neary N. Small C. Druce M. Park A. Ellis S. Semjonous N. et al. (2005) Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146: 5120–5127.
54. Orskov K. Bersani M. Johnsen A. Hojrup P. Holst J. (1989) Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem 264: 12826–12829.
55. Parker R. Herzog H. (1999) Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 11: 1431–1448.
56. Pocai A. Carrington P. Adams J. Wright M. Eiermann G. Zhu L. et al. (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58: 2258–2266.
57. Pournaras D. Osborne A. Hawkins S. Mahon D. Ghatei M. Bloom S. et al. (2010) The gut hormone response following Roux-en-Y gastric bypass: cross sectional and prospective study. Obes Surg 10: 56–60.
58. Punjabi M. Arnold M. Geary N. Langhans W. Pacheco-Lopez G. (2011) Peripheral Glucagon-like peptide-1 (GLP-1) and Satiation. Physiol Behav. DOI: 10.1016/j.physbeh.2011.2,038.
59. Ringbäck Weitoft G. Eliasson M. Rosén M. (2008) Underweight, overweight and obesity as risk factors for mortality and hospitalization. Scand J Public Health 36: 169–176.
60. Robles G. Singh-Franco D. (2009) A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Drug Des Devel Ther 21: 219–240.
61. Rucker D. Padwal R. Li S. Curioni C. Lau D. (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335: 1194–1199.
62. Schellekens H. Dinan T. Cryan J. (2010) Lean mean fat reducing “ghrelin” machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity. Neuropharmacology 58: 2–16.
63. Schirra J. Nicolaus M. Roggel R. Katschinski M. Storr M. Woerle H. et al. (2006) Endogenous glucagon-like peptide-1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in Humans. Gut 55: 243–251.
64. Schjoldager B. Mortensen P. Myhre J. Christiansen J. Holst J. (1989) Oxyntomodulin from distal gut. Role in regulation of gastric and pancreatic functions. Dig Dis Sci 34: 1411–1419.
65. Schmidt P. Näslund E. Grybäck P. Jacobsson H. Holst J. Hilsted L. et al. (2005) A role for pancreatic polypeptide in the regulation of gastric emptying and short-term metabolic control. J Clin Endocrinol Metab 90: 5241–5246.
66. Shearman L. Wang S. Helmling S. Stribling D. Mazur P. Ge L. et al. (2006) Ghrelin neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 147: 1517–1526.
67. Shechter Y. Tsubery H. Mironchik M. Rubinstein M. Fridkin M. (2005) Reversible PEGylation of peptide YY(3-36) prolongs its inhibition of food intake in mice. FEBS Lett 579: 2439–2444.
68. Shiiya T. Nakazato M. Mizuta M. Date Y. Mondal M. Tanaka M. et al. (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87: 240–244.
69. Sisson E. (2011) Liraglutide: clinical pharmacology and considerations for therapy. Pharmacotherapy 31: 896–911.
70. Sjostrom L. Narbro K. Sjostrom C. Karason K. Larsson B. Wedel H. et al. (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357: 741–752.
71. Smith B. Schauer P. Nguyen N. (2008) Surgical approaches to the treatment of obesity: bariatric surgery. Endocrinol Metab Clin N Am 37: 943–964.
72. Steinert R. Poller B. Castelli M. Drewe J. Beglinger C. (2010) Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am J Clin Nutr 92: 810–817.
73. Swanton K., for the National Heart Forum/Cross-Government Obesity Unit / Faculty of Public Health (2008) Healthy weight, healthy lives: a toolkit for developing local strategies. Available at: http://www.fph.org.uk/uploads/full_obesity_toolkit-1.pdf.
74. Tan T. Field B. McCullough K. Troke R. Chambers E. Salem V. et al. (2013) Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62: 1131–1138.
75. Tan T. Field B. Minnion J. Cuenco-Shillito J. Chambers E. Zac-Varghese S. et al. (2012) Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol 73: 232–239.
76. Tibble C. Cavaiola T. Henry R. (2013) Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes. Expert Rev Endocrinol Metab 8: 247–259.
77. Tong J. Prigeon R. Davis H. Bidlingmaier M. Tschöp M. D'Alessio D. (2013) Physiologic concentrations of exogenously infused ghrelin reduces insulin secretion without affecting insulin sensitivity in healthy humans. J Clin Endocrinol Metab 98: 2536–2543.
78. Wang G. Tomasi D. Backus W. Wang R. Telang F. Geliebter A. et al. (2008) Gastric distention activates satiety circuitry in the human brain. Neuroimage 39: 1824–1831.
79. Whitlock G. Lewington S. Sherliker P. Clarke R. Emberson J. Halsey J. et al. (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373: 1083–1096.
80. WHO (2012) World Health Statistics, World Health Organization. http://www.who.int/gho/publications/world_health_statistics.
81. Willesen M. Kristensen P. Rømer J. (1999) Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 70: 306–316.
82. Williams D. Grill H. Cummings D. Kaplan J. (2003) Vagotomy dissociates short- and long-term controls of circulating ghrelin. Endocrinology 144: 5184–5187.
83. Wynne K. Park A. Small C. Meeran K. Ghatei M. Frost G. et al. (2006) Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Intl J Obesity 30: 1729–1736.
84. Wynne K. Park A. Small C. Patterson M. Ellis S. Murphy K. et al. (2005) Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects. A double-blind, randomized, controlled trial. Diabetes 54: 2390–2395.
85. Yang J. Zhao T. Goldstein J. Brown M. (2008) Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci U S A 105: 10750–10755.
86. Zheng W. McLerran D. Rolland B. Zhang X. Inoue M. Matsuo K. et al. (2011) Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med 364: 719–729.
87. Zorrilla E. Iwasaki S. Moss J. Chang J. Otsuji J. Inoue K. et al. (2006) Vaccination against weight gain. Proc Natl Acad Sci U S A 103: 13226–13231.